12 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 8 Phase 3, 5 Phase 4, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 6, Not yet recruiting 1, Terminated 1 |
| Phase 4 | 5 | Completed 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 3 |
Follow vernakalant: new trials by email Literature Review of vernakalant trials Research Report on vernakalant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients Vernakalant, Amiodarone - Atrial Fibrillation, Post-cardiac Surgery | Phase 3 | Not yet recruiting | University of Calgary | 50 | 2026-09-01 | 2026-06-03 |
| RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department Vernakalant, Procainamide - Atrial Fibrillation | Phase 4 | Completed | Ottawa Hospital Research Institute | 350 | 2021-06-17 | 2025-04-10 |
| Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents Vernakalant, Flecainide - Paroxysmal Atrial Fibrillation | Phase 4 | Completed | David Filgueiras-Rama | 50 | 2017-01-01 | 2023-08-07 |
| A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055) Vernakalant, Amiodarone - Atrial Fibrillation | Phase 4 | Withdrawn | Advanz Pharma | 2012-09-01 | 2013-08-26 | |
| Vernakalant Versus Flecainide: Atrial Contractility Vernakalant, Flecainide - Atrial Fibrillation | Phase 4 | Unknown | Maastricht University Medical Center | 70 | 2012-08-01 | 2012-07-20 |
| Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation Brinavess (Vernakalant), Corvert (Ibutilide) - Atrial Fibrillation | Phase 4 | Completed | Medical University of Vienna | 101 | 2011-10-01 | 2015-05-13 |
| Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049) Vernakalant - Atrial Fibrillation | Completed | Correvio International Sarl | 2015 | 2011-08-01 | 2019-12-30 | |
| A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045) Vernakalant, Placebo - Atrial Fibrillation | Phase 3 | Terminated | Advanz Pharma | 217 | 2009-10-01 | 2014-03-10 |
| A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation Vernakalant Injection, Amiodarone Injection: - Atrial Fibrillation | Phase 3 | Completed | Advanz Pharma | 254 | 2008-04-01 | 2009-12-15 |
| Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study Placebo, Vernakalant (oral) - Atrial Fibrillation | Phase 2 | Completed | Advanz Pharma | 735 | 2007-03-01 | 2008-12-18 |
| Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence Vernakalant (oral), Placebo comparator - Atrial Fibrillation | Phase 2 | Completed | Advanz Pharma | 221 | 2005-12-01 | 2008-12-18 |
| Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation RSD1235 - Atrial Fibrillation | Phase 3 | Completed | Astellas Pharma Inc | 254 | 2005-10-01 | 2008-04-03 |
| Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery RSD1235 - Atrial Fibrillation, Atrial Flutter | Phase 3 | Completed | Astellas Pharma Inc | 190 | 2004-06-01 | 2007-12-24 |
| Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter RSD1235, placebo - Atrial Flutter, Atrial Fibrillation | Phase 3 | Completed | Astellas Pharma Inc | 276 | 2004-06-01 | 2008-04-01 |
| A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter Vernakalant Injection 20 mg/mL - Atrial Flutter | Phase 2 / Phase 3 | Completed | Advanz Pharma | 60 | 2003-08-01 | 2008-04-02 |
| Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation Vernakalant Injection 20 mg/mL - Atrial Fibrillation | Phase 3 | Completed | Advanz Pharma | 356 | 2003-08-01 | 2008-04-02 |
Atrial Fibrillation (15) · Atrial Flutter (3) · Emergencies (1)
Advanz Pharma (7) · Astellas Pharma Inc (3) · Correvio International Sarl (1) · David Filgueiras-Rama (1) · Maastricht University Medical Center (1) · Medical University of Vienna (1) · Ottawa Hospital Research Institute (1) · University of Calgary (1)
Denmark (9) · Canada (8) · Sweden (7) · United States (6) · Netherlands (4) · Argentina (3) · Germany (3) · Poland (3) · Spain (3) · Australia (2) · Austria (2) · Czechia (2) · Estonia (2) · Finland (2) · Lithuania (2)
Sheila Grant, MBA (2) · Christian Torp-Pedersen, MD (1) · Etienne Aliot, MD (1) · Greg Beatch, PhD (1) · Gregory Beatch, PhD (1) · Harry Crijns, MD, PhD (1) · Heikki Huikuri, MD (1) · Ian G Stiell, MD, MSc (1) · Michael Chiu, MD, MSC (1) · Piotr Ponikowski, MD (1)
PMID 21175515, PMID 18332267, PMID 19948506, PMID 20569725, PMID 21232669, PMID 21841207, PMID 22291438, PMID 27233239, PMID 28175295, PMID 41218981